BR9913435A - Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica - Google Patents

Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica

Info

Publication number
BR9913435A
BR9913435A BR9913435-7A BR9913435A BR9913435A BR 9913435 A BR9913435 A BR 9913435A BR 9913435 A BR9913435 A BR 9913435A BR 9913435 A BR9913435 A BR 9913435A
Authority
BR
Brazil
Prior art keywords
human
compositions
mammal
vector
treating
Prior art date
Application number
BR9913435-7A
Other languages
English (en)
Inventor
Camellia W Adams
Brigitte Devaux
Dan L Eaton
Philip E Hass
J Kevin Judice
Daniel Kirchhofer
Shelley Suggett
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR9913435A publication Critical patent/BR9913435A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

<B>"COMPOSIçõES COMPREENDENDO ANTICORPOS ANTI-FATOR IX/IXa HUMANOS, áCIDO NUCLéICO ISOLADO, VETOR, CéLULA HOSPEDEIRA, MéTODO DE PRODUçãO DE ANTICORPO OU FRAGMENTO DE ANTICORPO, ARTIGO INDUSTRIALIZADO, MéTODO DE TRATAMENTO DE UM MAMìFERO E COMPOSIçãO FARMACêUTICA"<D> A presente invenção proporciona o isolamento, identificação, síntese, expressão e purificação de anticorpos reativos com fator IX (FIX)/fator IXa (IXa). Em aspectos específicos, a presente invenção proporciona anticorpos humanos reativos com o domínio Gla de FIX humano. A presente invenção proporciona adicionalmente composições, especialmente composições farmacêuticas, artigos industrializados e métodos de inibição da ativação de FIX e inibição da coagulação dependente de FIX/IXa.
BR9913435-7A 1998-08-28 1999-08-26 Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica BR9913435A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9823398P 1998-08-28 1998-08-28
US12276799P 1999-03-03 1999-03-03
PCT/US1999/019453 WO2000012562A1 (en) 1998-08-28 1999-08-26 HUMAN ANTI-FACTOR IX/IXa ANTIBODIES

Publications (1)

Publication Number Publication Date
BR9913435A true BR9913435A (pt) 2001-09-25

Family

ID=26794469

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913435-7A BR9913435A (pt) 1998-08-28 1999-08-26 Composições compreendendo anticorpos anti-fator ix/ixa humanos, ácido nucléico isolado, vetor, célula hospedeira, método de produção de anticorpo ou fragmento de anticorpo, artigo industrializado, método de tratamento de um mamìfero e composição farmacêutica

Country Status (15)

Country Link
US (3) US6624295B1 (pt)
EP (1) EP1107996B1 (pt)
JP (1) JP4638035B2 (pt)
CN (1) CN1183160C (pt)
AT (1) ATE217889T1 (pt)
AU (1) AU766551C (pt)
BR (1) BR9913435A (pt)
CA (1) CA2341276C (pt)
DE (1) DE69901569T2 (pt)
DK (1) DK1107996T3 (pt)
ES (1) ES2177316T3 (pt)
IL (1) IL140917A0 (pt)
NZ (1) NZ509430A (pt)
PT (1) PT1107996E (pt)
WO (1) WO2000012562A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
SE0000675D0 (sv) * 2000-03-02 2000-03-02 Protease Ab Monoclonal antibodies
DE10012732A1 (de) * 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
CN100339132C (zh) * 2000-05-15 2007-09-26 史密丝克莱恩比彻姆公司 抗血栓剂
GB2378949B (en) * 2001-08-16 2005-09-07 Morten Steen Hanefeld Dziegiel Recombinant anti-plasmodium falciparum antibodies
DE10311248A1 (de) 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
GB0309126D0 (en) * 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
EP1531162A1 (en) * 2003-11-14 2005-05-18 Heinz Vollmers Adenocarcinoma specific antibody SAM-6, and uses thereof
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
DK1905839T4 (da) * 2006-09-22 2019-10-07 Wacker Chemie Ag Fremgangsmåde til fermentativ fremstilling af proteiner
WO2010045388A2 (en) * 2008-10-14 2010-04-22 Dyax Corp. Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
AU2011234521B2 (en) * 2010-03-30 2015-04-23 Octapharma Ag A process for purifying Vitamin K dependent proteins such as coagulation factor IX
WO2011121031A1 (en) 2010-03-30 2011-10-06 Octapharma Ag Process for the purification of a growth factor protein
CA2796010C (en) * 2010-04-13 2020-05-12 Medimmune, Llc Trail r2-specific multimeric scaffolds
WO2012161226A1 (ja) * 2011-05-23 2012-11-29 積水メディカル株式会社 Pivka-ii測定試薬における非特異反応の抑制方法
US9623118B2 (en) * 2015-09-01 2017-04-18 Immunwork Inc. Multi-arm linker constructs for treating pathological blood clots
US20200231701A1 (en) * 2016-12-23 2020-07-23 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
KR20190112747A (ko) 2017-02-01 2019-10-07 노보 노르디스크 에이/에스 응고촉진 항체
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN115448985A (zh) * 2021-06-08 2022-12-09 上海循曜生物科技有限公司 新型抗栓抗体
CN116333145B (zh) * 2023-04-14 2023-11-07 北京基科晟斯医药科技有限公司 结合活化凝血因子ix的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3720983A1 (de) * 1987-06-25 1989-01-05 Hoechst Ag Immunometrisches bestimmungsverfahren
WO1991016353A1 (en) 1990-04-23 1991-10-31 Corvas International N.V. Thrombus-specific antibody derivatives
EP0614984B2 (en) 1993-03-05 2010-11-03 Bayer HealthCare LLC Anti-TNF alpha human monoclonal antibodies
ES2191702T3 (es) 1994-03-17 2003-09-16 Merck Patent Gmbh Fv monocatenarios anti-egfr y anticuerpos anti-egfr.
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose

Also Published As

Publication number Publication date
JP4638035B2 (ja) 2011-02-23
US7049411B2 (en) 2006-05-23
US6624295B1 (en) 2003-09-23
EP1107996B1 (en) 2002-05-22
WO2000012562A1 (en) 2000-03-09
US20060088534A1 (en) 2006-04-27
AU766551B2 (en) 2003-10-16
DK1107996T3 (da) 2002-09-16
EP1107996A1 (en) 2001-06-20
CN1183160C (zh) 2005-01-05
AU766551C (en) 2005-02-17
NZ509430A (en) 2002-04-26
AU5692399A (en) 2000-03-21
PT1107996E (pt) 2002-10-31
US20060193851A1 (en) 2006-08-31
CA2341276A1 (en) 2000-03-09
IL140917A0 (en) 2002-02-10
CA2341276C (en) 2005-10-11
ATE217889T1 (de) 2002-06-15
ES2177316T3 (es) 2002-12-01
US7354585B2 (en) 2008-04-08
JP2002523081A (ja) 2002-07-30
DE69901569T2 (de) 2002-12-19
CN1317015A (zh) 2001-10-10
DE69901569D1 (de) 2002-06-27

Similar Documents

Publication Publication Date Title
PT1107996E (pt) Anticorpos humanos anti-factor ix/ixa
Holman et al. Photolabelling of the hexose transporter at external and internal sites: fragmentation patterns and evidence for a conformational change
ATE373719T1 (de) Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
EP3805248A3 (en) Process for concentration of antibodies and therapeutic products thereof
BR9910089A (pt) Composições e antìgenos de neisseria meningitidis
WO2002020569A3 (en) Mammalian genes; related reagents and methods
ATE382053T1 (de) System zur antikörperexpression und- synthese
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
Preissner et al. Domain structure of the endothelial cell receptor thrombomodulin as deduced from modulation of its anticoagulant functions. Evidence for a glycosaminoglycan-dependent secondary binding site for thrombin.
ITMI20011986A0 (it) Metodo e composizione per l&#39;attivazione di cellule presentanti l&#39;antigene
TR200002731T2 (tr) Proteolitik antikorların indüktör ve inhibitörlerinin tanımlanması, kompozisyonları ve kullanımları için metotlar
WO2003092630A3 (en) Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
CY1109518T1 (el) Αναστολεας ενεργοποιητη αυξητικου παραγοντα ηπατοκυτταρων για χρηση σε διαμορφωση αγγειογενεσης και καρδιοαγγειωσης
FI20011664A7 (fi) Syöpäpesifiset oligoskkaridisekvenssit ja niiden käyttö
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
Ara et al. Reactive oxygen species modified DNA fragments of varying size are the preferred antigen for human anti-DNA autoantibodies
PT935652E (pt) Produtos de factor de crescimento de queratinocitos-2
AU2001289034A1 (en) Novel pdes and uses thereof
EP1422243A4 (en) HUMANIZED ANTIBODY AGAINST FIBROBLAST GROWTH FACTOR 8 AND FRAGMENT OF THE ANTIBODY
Rodgers et al. Activation of coagulation factor V by calcium-dependent proteinase
WO2001004143A3 (en) Prostase vaccine
WO2003060067A3 (en) P85-alpha nucleic acids, polypeptides and related methods
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
Long et al. Probing plasma clearance of the thrombin–antithrombin complex with a monoclonal antibody against the putative serpin–enzyme complex receptor‐binding site
Hayashi-Nagai et al. Hydrophobic properties of porcine fibronectin and its functional domains

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2256 DE 01/04/2014.